Vitisin B, a resveratrol tetramer from Vitis thunbergii var. taiwaniana, ameliorates impaired glucose regulations in nicotinamide/streptozotocin-induced type 2 diabetic mice

Yuh-Hwa Liu; Yin-Shiou Lin; Yi-Yan Sie; Ching-Chiung Wang; Chi-I Chang; Wen-Chi Hou

doi:10.1016/j.jtcme.2023.05.003

Vitisin B, a resveratrol tetramer from Vitis thunbergii var. taiwaniana, ameliorates impaired glucose regulations in nicotinamide/streptozotocin-induced type 2 diabetic mice

J Tradit Complement Med. 2023 May 30;13(5):479-488. doi: 10.1016/j.jtcme.2023.05.003. eCollection 2023 Sep.

Authors

Yuh-Hwa Liu^{1

2}, Yin-Shiou Lin³, Yi-Yan Sie⁴, Ching-Chiung Wang^{4

5}, Chi-I Chang⁶, Wen-Chi Hou³

Affiliations

¹ Department of General Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan.
² Division of Gastroenterology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, 111, Taiwan.
³ Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, 110, Taiwan.
⁴ Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
⁵ School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, 110, Taiwan.
⁶ Department of Biological Science and Technology, National Pingtung University of Science and Technology, Pingtung, 912, Taiwan.

Abstract

Background and aim: In Taiwan, Vitis thunbergii var. taiwaniana (VTT) is used in traditional medicine and as a local tea. VTT rich in resveratrol and resveratrol oligomers have been reported to exhibit anti-obesity and anti-hypertensive activities in animal models; however, no studies have investigated type 2 diabetes mellitus (T2DM) treatments. This study aimed to investigate the anti-T2DM effects of resveratrol tetramers isolated from the VTT in nicotinamide/streptozotocin (STZ)-induced Institute of Cancer Research (ICR) mice.

Experimental procedure: The oral glucose tolerance test (OGTT) was used to imitate postprandial blood glucose (BG) regulations in mice by pre-treatment with VTT extracts, resveratrol tetramers of vitisin A, vitisin B, and hopeaphenol 30 min before glucose loads. Vitisin B (50 mg/kg) was administered to treat T2DM-ICR mice once daily for 28 days to investigate its hypoglycemic activity.

Results and conclusion: Mice pre-treated with VTT-S-95EE, or vitisin B (100 mg/kg) 30-min before glucose loading showed significant reductions (P < 0.001) in the area under the curve at 120-min (BG-AUC_0-120) than those without pre-treatment with VTT-S-95 E E or vitisin B. Vitisin B-treated T2DM mice showed hypoglycemic activities via a reduction in plasma dipeptidyl peptidase (DPP)-IV activities to maintain insulin actions and differed significantly than those of untreated T2DM mice (P < 0.05), and also reduced BG-AUC_0-120 and insulin-AUC_0-120 in the OGTT.These in vivo results showed that VTT containing vitisin B would be beneficial for developing nutraceuticals and/or functional foods for glycemic control in patients with T2DM, which should be investigated further.

Keywords: Nutraceuticals; Resveratrol tetramers of vitisin a; Type 2 diabetes mellitus (T2DM); Vitis thunbergii var. taiwaniana (VTT); Vitisin B; and hopeaphenol.